Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solabegron dose-ranging proof-of-concept study in women with overactive bladder
2005-005431-97Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Solabegron in overactive bladder (OAB) (4 arms), sponsored by GSK. Primary endpoint: Percentage change from baseline to week 8 in number of incontinence episodes per 24 hours. Started Jan 2006; status: completed.
02
Drugs
Solabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2005-005431-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005431-97.